Table 1.

The association between nirmatrelvir therapy and COVID-19–related hospitalization or death was estimated with the use of a multivariate Cox proportional–hazards regression model after adjustment for confounding factors

Variable	HR for COVID-19–related hospitalization or death	P value
Age	1.05 (1.03-1.07)	<.001∗
Number of previous CLL treatments	1.39 (1.17-1.65)	<.001∗
Recent hospitalizations†	1.92 (1.25-2.95)	.0027‡
IVIG treatment	1.96 (1.2-3.4)	.019§
Nirmatrelvir	0.48 (0.13-0.63)	.002‡
Previous COVID-19 infection	0.22 (0.07-0.72)	.0199§
Doses of COVID-19 vaccine|| before infection	0.75 (0.63-0.89)	<.001∗
Recent melanoma†	1.79 (1.09-2.94)	.0213§
Recent other malignancy†	0.42 (0.19-0.91)	.0284§
Asthma	2.66 (1.22-5.81)	.0141§
Myeloproliferative diseases	3.19 (1.58-6.43)	.0012‡
Chronic kidney disease status	1.1 (0.62-1.95)	.667

Variables that met the testing criteria and were significantly associated with the outcome served as the inputs for the multivariate regression analysis. IVIG, intravenous immunoglobulin.

^∗Very highly statistically significant at the level 0.001

^†Recent refers to last 3 years.

^‡Highly statistically significant at the level 0.01

^§Statistically significant at the level 0.05

^||Number of doses counts both messenger RNA–based vaccines (mainly Pfizer) and passive vaccines (75 patients received tixagevimab and cilgavimab).